Diindolylmethane Dosing for Breast Cancer Risk Reduction
Based on the highest quality clinical evidence, 100 mg of diindolylmethane (DIM) once daily has been shown to reduce breast density—a recognized predictive factor for breast cancer risk—in BRCA carriers over one year of supplementation. 1
Evidence-Based Dosing
The most rigorous clinical trial examining DIM for breast cancer risk reduction used 100 mg once daily in healthy BRCA mutation carriers 1. This prospective study demonstrated:
- Significant reduction in fibroglandular tissue (FGT) amount on MRI after 1 year (P = 0.031), while untreated matched controls showed no change 1
- Decreased estradiol levels from 159 to 102 pmol/L (P = 0.01) 1
- Decreased testosterone levels from 0.42 to 0.31 pmol/L (P = 0.007) 1
- Only grade 1 side effects reported 1
Alternative Dosing Studied
A separate randomized controlled trial used 150 mg twice daily (300 mg total) in women already taking tamoxifen for breast cancer 2. While this higher dose showed favorable changes in estrogen metabolism and increased sex hormone-binding globulin, it also:
- Significantly reduced tamoxifen metabolites, including endoxifen (P < 0.001), which could potentially attenuate tamoxifen's clinical benefit 2
- Did not demonstrate reduction in breast density by mammography or MRI 2
Critical Clinical Considerations
For women on hormone therapy or tamoxifen, DIM supplementation requires careful consideration due to documented drug-supplement interactions:
- DIM alters estrogen metabolism in postmenopausal women using transdermal estradiol patches, affecting 6 of 10 measured estrogen metabolites 3
- The combination with tamoxifen reduces active tamoxifen metabolites, which may compromise treatment efficacy 2
Guideline perspective: Cruciferous vegetables containing 3'-diindolylmethane demonstrate chemopreventive activities across all stages of breast cancer carcinogenesis, with dietary intake of approximately 57 g/day of cruciferous vegetables considered protective 4
Practical Recommendation
For breast cancer risk reduction in healthy women (particularly BRCA carriers): 100 mg once daily represents the evidence-based dose with demonstrated efficacy on breast density reduction and favorable hormonal changes 1. This dose aligns with common supplement formulations containing 150 mg DIM per capsule 5, though the clinical trial used 100 mg specifically.
Avoid DIM supplementation or consult oncology if currently taking tamoxifen or other hormonal therapies due to potential interference with treatment efficacy 2, 3.